Trial Profile
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Niraparib (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MAGNITUDE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 27 Jan 2024 Results assessing Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer presented at the 2024 Genitourinary Cancers Symposium
- 24 Jan 2024 According to a Johnson & Johnson media release, patient-reported outcomes data from this study will be presented at the ASCO GU Symposium (San Francisco, January 25-27).
- 31 Oct 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.